Abstract
Neonatal infections continue to cause morbidity and mortality in infants. Among approximately 400,000 infants followed nationally, the incidence rates of early-onset sepsis infection within 3 days of life are 0.98 cases per 1000 live births. Newborn infants are at increased risk for infections because they have relative immunodeficiency. This article provides evidence-based practical approaches to the diagnosis, management, and prevention of neonatal infections.
Keywords:
Antibacterial therapy; Antiviral therapy; Early-onset sepsis; Late-onset sepsis; Neonatal antimicrobial stewardship; Neonatal infections; Newborn sepsis; Respiratory viral infections in infants.
Copyright © 2015 Elsevier Inc. All rights reserved.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Antifungal Agents / therapeutic use
-
Antiviral Agents / therapeutic use
-
Bacterial Infections / diagnosis*
-
Bacterial Infections / prevention & control
-
Bacterial Infections / therapy*
-
Bacterial Infections / transmission
-
Ganciclovir / analogs & derivatives
-
Ganciclovir / therapeutic use
-
Humans
-
Hygiene
-
Infant, Newborn
-
Mycoses / diagnosis*
-
Mycoses / prevention & control
-
Mycoses / therapy*
-
Mycoses / transmission
-
Prebiotics
-
Probiotics / therapeutic use
-
Sepsis / diagnosis
-
Sepsis / therapy
-
Valganciclovir
-
Virus Diseases / diagnosis*
-
Virus Diseases / prevention & control
-
Virus Diseases / therapy*
-
Virus Diseases / transmission
Substances
-
Anti-Bacterial Agents
-
Antifungal Agents
-
Antiviral Agents
-
Prebiotics
-
Valganciclovir
-
Ganciclovir